← Eichor
Condition: Relapsed Or Refractory Peripheral T Cell Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed Or Refractory Peripheral T Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06244368A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06914037Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Phase 2 · 6 location(s) · University of Virginia · NCT04747236A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06855823A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Perip
Phase 3 · 1 location(s) · Evopoint Biosciences Inc. · NCT06776952Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a Ne
Phase 1/Phase 2 · 8 location(s) · Instituto de Investigación Biomédica de Salamanca · NCT06378190Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT06934382Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT06176690Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2 · 6 location(s) · Great Novel Therapeutics Biotech & Medicals Corporation · NCT05833724CD4CAR for CD4+ Leukemia and Lymphoma
Phase 1 · 6 location(s) · Huda Salman · NCT03829540Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Rong Tao · NCT07502768Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07093710Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT04288726RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
Phase 2 · 1 location(s) · Xianmin Song, MD · NCT06468267Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Phase 2 · 2 location(s) · Yale University · NCT05996185Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell
Phase 1/Phase 2 · 4 location(s) · City of Hope Medical Center · NCT03011814Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Re
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07225985Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · 34 location(s) · Corvus Pharmaceuticals, Inc. · NCT06561048Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Phase 1 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT05079282Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT06793956A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Se
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06966154Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase 2 · 1 location(s) · National Cancer Centre, Singapore · NCT06160843A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/S
Phase 1 · 14 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06547528A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 · 15 location(s) · Prescient Therapeutics, Ltd. · NCT06854653Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06732492Evaluate the Safety and Clinical Activity of HH2853
Phase 1/Phase 2 · 25 location(s) · Haihe Biopharma Co., Ltd. · NCT04390737Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Phase 1 · 2 location(s) · Mayo Clinic · NCT06508463
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.